- Home
- BLNK vs CUE Comparison
BLNK vs CUE Comparison
Compare BLNK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- CUE
- Stock Information
- Founded
- BLNK 2009
- CUE 2014
- Country
- BLNK United States
- CUE United States
- Employees
- BLNK 706
- CUE N/A
- Industry
- BLNK Industrial Specialties
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- CUE Health Care
- Exchange
- BLNK Nasdaq
- CUE Nasdaq
- Market Cap
- BLNK 103.7M
- CUE 94.4M
- IPO Year
- BLNK N/A
- CUE 2018
- Fundamental
- Price
- BLNK $1.03
- CUE $1.32
- Analyst Decision
- BLNK Buy
- CUE Strong Buy
- Analyst Count
- BLNK 8
- CUE 5
- Target Price
- BLNK $5.24
- CUE $5.00
- AVG Volume (30 Days)
- BLNK 4.1M
- CUE 191.3K
- Earning Date
- BLNK 03-13-2025
- CUE 03-10-2025
- Dividend Yield
- BLNK N/A
- CUE N/A
- EPS Growth
- BLNK N/A
- CUE N/A
- EPS
- BLNK N/A
- CUE N/A
- Revenue
- BLNK $138,728,000.00
- CUE $9,532,000.00
- Revenue This Year
- BLNK N/A
- CUE $73.11
- Revenue Next Year
- BLNK $22.16
- CUE $11.02
- P/E Ratio
- BLNK N/A
- CUE N/A
- Revenue Growth
- BLNK 15.13
- CUE 149.53
- 52 Week Low
- BLNK $0.92
- CUE $0.45
- 52 Week High
- BLNK $3.75
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- BLNK 29.72
- CUE 48.32
- Support Level
- BLNK $0.92
- CUE $1.22
- Resistance Level
- BLNK $1.19
- CUE $1.54
- Average True Range (ATR)
- BLNK 0.07
- CUE 0.11
- MACD
- BLNK 0.00
- CUE -0.01
- Stochastic Oscillator
- BLNK 36.21
- CUE 35.29
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.